Published:
Psilocybe Cubensis
"Golden Cap, Cubes, Golden Teacher"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/Cubensis5_new-800x450.webp)
Scientific Classification
About
Psilocybe cubensis, commonly known as the Golden Cap, Cubes, or Magic Mushroom, is the most well-known and widely cultivated psychedelic mushroom species in the world. Recognized by its golden-brown cap and strong bluing reaction when bruised, P. cubensis contains the psychoactive compounds psilocybin and psilocin, which induce altered perception, vivid visuals, and spiritual introspection.
History
First scientifically described in the early 20th century, Psilocybe cubensis has been used for centuries in shamanic traditions, particularly in Mesoamerican cultures, where its sacred use dates back to pre-Columbian times. Its popularity exploded in the West during the 1960s counterculture movement and continued with the rise of home cultivation following the publication of guides by mycologists like Terence McKenna.
Golden Cap is one of many informal names, referring specifically to strains of P. cubensis with a bright, golden center on the cap. Its global adaptability and easy cultivation have made it a staple in both recreational and therapeutic psychedelic use.
Overview
The mushroom features a broad, convex to flat cap (up to 8 cm) with a golden center, fading toward the edge. The gills are initially pale and turn dark purple-brown as spores mature. The stem is white to yellowish, hollow, and bruises blue when damaged.
Golden Cap mushrooms are usually consumed dried or fresh, with effects lasting 4–6 hours. They can induce euphoria, visual distortions, time dilation, and deep emotional or spiritual experiences. They are often used in clinical research for their promising effects on depression, PTSD, and addiction.
Physical Characteristics
Caps:
Golden to reddish-brown, smooth, with a diameter of 2-8 cm
Gills:
Adnate to adnexed, initially grayish-purple, darkening to purplish-black with age
Psychoactive Effects
Euphoric
Describing intense feelings of happiness or excitement
Perceptual
The change in the way things are perceived, including changes in time perception, spatial perception, and perception of one's own body.
Pharmacology
Helps With
Depression
Relieves symptoms of depression, improving mood and outlook
Anxiety
Helps to alleviate feelings of worry, fear, and unease
Addiction
Helps to overcome addiction and substance abuse
PTSD
Helps to alleviate symptoms of post-traumatic stress disorder
OCD
Helps to alleviate symptoms of obsessive-compulsive disorder
ADD ADHD
Helps to alleviate symptoms of attention deficit disorder and attention deficit hyperactivity disorder
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines. A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
A feeling of discomfort in the stomach with an urge to vomit
Grow at Home
Start your cultivation journey with quality grow kits from verified vendors
Chemical Constituents
Medicinal Chemistry
Similar Species
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeSubcubensis_new-400x400.webp)
Species: Psilocybe Subcubensis
Edibility: Psychoactive
Key Differences: P. subcubensis has a more slender stem and smaller cap compared to P. cubensis.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeSubcubensis_new-400x400.webp)
Species: Psilocybe Subcubensis
Edibility: Psychoactive
Mushroom Ratings
5.0
(1)
Based on 1 Review
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
01/29/2025
Zaky J
References
- Bradshaw, A. ., Ramírez-Cruz, V., & Dentinger , B. (2024). Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster. .
- Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., & Gordon, E. M. (2024). Psilocybin desynchronizes the human brain. .
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- McKernan, K., Kane, L., Helbert, Y., Zhang, L., Houde, N., & McLaughlin, S. (2021). A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .